OncoGenex announces update on phase 3 ENSPIRIT trial evaluating custirsen
OncoGenex announced the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee based upon completion of the first interim futility analysis. August 21, 2014